genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Multiple myeloma
Cancer
Multiple Myeloma Patient Survival Associated with ADAR1 Enzyme Levels
Cancer
A Cancer Cell’s Weight Predicts Its Therapeutic Opponent
Cancer
Celgene Agrees to Pay $280M in Whistleblower Suit Settlement
Cancer
Janssen, Adaptive to Develop clonoSEQ for Measuring MRD in Darzalex-Treated MM
Cancer
Merck & Co. Halts Enrollment in Two Keytruda Trials, Citing Deaths
Drug Discovery
EC Clears Janssen’s Daratumumab as Combination Therapy for Multiple Myeloma
Cancer
Liquid Biopsies Provide Patients with Less Painful Test for Multiple Myeloma
Industry News
A Year into Job, Celgene President and COO Said to Retire
A-Lists
Top 10 M&A Deals of 2016
Insights
Supplement: Treating “Solid” Tumors with CAR T Cells
1
...
4
5
6
...
15
Page 5 of 15
Scroll Up
Scroll Up
